Celgene Corporation (CELG) Shares Sold by PNC Financial Services Group Inc.
PNC Financial Services Group Inc. trimmed its stake in shares of Celgene Corporation (NASDAQ:CELG) by 1.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 772,994 shares of the biopharmaceutical company’s stock after selling 14,052 shares during the quarter. PNC Financial Services Group Inc. owned approximately 0.10% of Celgene Corporation worth $100,388,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in CELG. Thompson Davis & CO. Inc. grew its holdings in Celgene Corporation by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares during the last quarter. Motco grew its holdings in Celgene Corporation by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 159 shares during the last quarter. Penserra Capital Management LLC bought a new stake in Celgene Corporation during the 2nd quarter worth approximately $129,000. Acropolis Investment Management LLC bought a new stake in Celgene Corporation during the 2nd quarter worth approximately $144,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in Celgene Corporation by 47.5% during the 1st quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 380 shares during the last quarter. Institutional investors and hedge funds own 79.48% of the company’s stock.
In related news, insider Terrie Curran sold 1,727 shares of the stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the transaction, the insider now owns 3,925 shares in the company, valued at $564,768.25. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the transaction, the director now owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 20,227 shares of company stock valued at $2,843,956. 0.95% of the stock is owned by company insiders.
A number of equities research analysts have weighed in on CELG shares. Morgan Stanley lowered shares of Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 target price on the stock. in a report on Thursday, October 5th. BTIG Research reissued a “hold” rating on shares of Celgene Corporation in a report on Sunday, October 22nd. Cantor Fitzgerald reissued a “hold” rating and set a $112.00 target price on shares of Celgene Corporation in a report on Monday, October 30th. Vetr raised shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $144.39 price objective on the stock in a research note on Monday, October 23rd. Finally, Citigroup Inc. lowered shares of Celgene Corporation from a “buy” rating to a “neutral” rating in a research note on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and two have given a strong buy rating to the stock. Celgene Corporation currently has a consensus rating of “Buy” and an average target price of $139.57.
Celgene Corporation (NASDAQ CELG) opened at $104.50 on Wednesday. The firm has a market cap of $81,211.74, a PE ratio of 16.12, a P/E/G ratio of 0.80 and a beta of 1.79. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. Celgene Corporation has a 1 year low of $94.55 and a 1 year high of $147.17.
Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.58 earnings per share. equities analysts forecast that Celgene Corporation will post 6.67 EPS for the current year.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.